References
- Jensen L E, Whitehead A S. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998; 334: 489–503
- Stone M J. Amyloidosis: a final common pathway for protein deposition in tissues. Blood 1990; 75: 531–545
- Zhu L C, Sidhu G S, Yee H T, Cassai N D, Goldfarb D S, Wieczorek R L. AA-type amyloidosis associated with non-Hodgkin's lymphoma: a case report. Hum Pathol 2004; 35: 1041–1044
- Pamuk G E, Demir M, ÖruÜm H, Turgut B, Özyilmaz F, TekgÜndÜz E. Secondary amyloidosis causing nephrotic syndrome in a patient with non-Hodgkin's lymphoma: quite a rare diagnosis. Clin Lab Haematol 2006; 28: 259–261
- Xicoy B, Ribera J M, Vaquero M, Grau J, Milla F, Feliu E. AA-type amyloid tumor as an unsuspected cause of residual mass in a patient with large B-cell non-Hodgkin's lymphoma. LeukLymphoma 2002; 43: 681–682
- Castell J V, Gomez-Lechon M J, David M, Andus T, Geiger T. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237–239
- Monshage H J, Roelofs H M, van Pelt J F, Hazenberg B P. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988; 155: 112–117
- Hiasa Y, Konishi N, Kitahori Y, Yuasa T, Fujita T, Hirao Y, et al. Secondary systemic amyloidosis with Hodgkin's disease. Acta Pathol Jpn 1983; 33: 1069–1077
- Tanaka K, Horita M, Shibayama H, Seike M, Itoh Y, Hamaguchi K, et al. Secondary amyloidosis associated with Castleman's disease. Intern Med 1995; 34: 122–126
- Feldmann G, Nischalke H D, Nattermann J, Banas B, Berg T, Teschendorf C, et al. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 4491–4498
- Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217–2224
- Dispenzieri A, Kyle R A, Lacy M Q, Therneau T M, Larson D R, Plevak M F, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103: 3960–3963
- Karsenty G, Ulmann A, Droz D, Carnot F, Grunferd J P. Clinical and histological resolution of systemic amyloidosis after renal cell carcinoma removal. Nephron 1985; 40: 232–234